Rebus Holdings Inc Quick Ratio (NSPX) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Rebus Holdings Inc   (NSPX)

Rebus Holdings Inc 's Quick Ratio

NSPX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Quick Ratio deteriorated to 0 a new company low.

Within Major Pharmaceutical Preparations industry 636 other companies have achieved higher Quick Ratio than Rebus Holdings Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 4659 to 5968.

Explain Quick Ratio?
How much Cash & cash equivalents NSPX´s has?
What are NSPX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NSPX Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change -8.75 % 6.49 % -6.84 % -9.56 % -52.92 %
Y / Y Cash & cash equivalent Change -98.11 % -99.15 % -99.3 % -86.53 % -76.55 %
Quick Ratio MRQ 0 0 0 0.02 0.04
NSPX's Total Ranking # 5968 # 4659 # 5375 # 4756 # 4906
Seq. Current Liabilities Change -0.76 % 8.01 % -8.21 % -7.26 % 15.82 %
Seq. Cash & cash equivalent Change 0 % 0 % -96.27 % -49.43 % -54.86 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 637
Healthcare Sector # 1276
Overall Market # 5968


Quick Ratio Statistics
High Average Low
0.24 0.04 0
(Jun 30 2016)   (Jun 30 2018)




Financial Statements
Rebus Holdings Inc 's Current Liabilities $ 6 Millions Visit NSPX's Balance sheet
Rebus Holdings Inc 's Cash & cash equivalent $ 0 Millions Visit NSPX's Balance sheet
Source of NSPX's Sales Visit NSPX's Sales by Geography


Cumulative Rebus Holdings Inc 's Quick Ratio

NSPX's Quick Ratio for the trailling 12 Months

NSPX Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -5.05 % -24.94 % -59.31 % -59.79 % -61.25 %
Y / Y Cash & cash equivalent TTM Growth -94.18 % -88.05 % -72.43 % -41.8 % 25.58 %
Quick Ratio TTM 0.01 0.02 0.04 0.07 0.11
Total Ranking TTM # 4375 # 4125 # 4122 # 3180 # 4475
Seq. Current Liabilities TTM Growth -2.37 % 1.54 % -1.69 % -2.58 % -22.82 %
Seq. Cash & cash equivalent TTM Growth -63.57 % -58.73 % -41.6 % -33.66 % -25.27 %

Quick ratio ranking by company, industry and sector >> Back to NSPX Financial Strength Comparisons >> Go to Compare NSPX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in NSPX's Current Liabilities to $5.62 millions, cumulative Quick Ratio to 0.01 below the NSPX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 552 other companies have achieved higher Quick Ratio than Rebus Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 4125 to 4375.

Explain Quick Ratio?
How much Cash & cash equivalents NSPX´s has?
What are NSPX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 553
Healthcare Sector # 1124
Within the Market # 4375


trailing twelve months Quick Ratio Statistics
High Average Low
0.11 0.04 0
(Mar 31 2022)   (Jun 30 2018)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
REST EZ Inc. 0.00 $ 0.000  Millions$ 0.042  Millions
Actavia Life Sciences Inc 0.00 $ 0.002  Millions$ 1.697  Millions
Skinvisible Inc 0.00 $ 0.004  Millions$ 2.980  Millions
Aridis Pharmaceuticals Inc 0.00 $ 0.019  Millions$ 20.394  Millions
Theralink Technologies Inc 0.00 $ 0.045  Millions$ 48.081  Millions
Rebus Holdings Inc 0.00 $ 0.005  Millions$ 5.619  Millions
60 Degrees Pharmaceuticals Inc 0.00 $ 0.019  Millions$ 28.863  Millions
Respirerx Pharmaceuticals Inc 0.00 $ 0.007  Millions$ 12.210  Millions
Rapid Therapeutic Science Laboratories Inc 0.00 $ 0.002  Millions$ 4.426  Millions
IMPACT BIOMEDICAL INC. 0.00 $ 0.003  Millions$ 12.055  Millions

Date modified: 2026-09-08T15:11:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.